このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

動脈瘤性くも膜下出血管理における血小板活性誘導抑制-2(iSPASM-2) (iSPASM-2)

2026年11月2日 更新者:Dr David Hasan, M.D.

動脈瘤性くも膜下出血管理における血小板活性の誘導的抑制-2

An exploratory, randomized, double-blinded, placebo-controlled, two-center clinical trial to determine the maximum tolerated dosage of intravenous tirofiban in patients with aneurysmal subarachnoid hemorrhage (aSAH) post-endovascular coiling. The study will also assess pharmacology and safety, with exploratory endpoints including delayed cerebral ischemia (DCI), vasospasm, and functional outcomes.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

This is an exploratory, two-center, randomized, double-blinded study. The primary objective is to determine the maximum tolerated dosage (MTD) of tirofiban in the context of patients with aSAH status post-endovascular coiling. The dosage regimen of tirofiban will be 0.10µg/kg/min (actual weight) within 48 hours of aneurysm securing and within 72 hours of ictus.

The study will involve a dose escalation stage and a cohort expansion stage. During the dosage-escalation stage, the intervention doses include continuous intravenous (IV) tirofiban or IV placebo for 1 day, 3 days, 5 days, or 7 days. Dose-escalation will follow the time-to-event Bayesian Optimal Intervention (TITE-BOIN) design. Unlike the majority of existing phase I designs, which require suspending the accrual after treating each cohort of patients, the TITE-BOIN design allows for real-time dose assignment decisions for new patients while the toxicity data are still pending for some patients under treatment. This shortens the trial duration and reduces the logistical difficulties caused by frequent suspensions of accrual. For parallel comparison under real-world conditions, patients will be randomly assigned to tirofiban and placebo in a 2:1 ratio in the dose escalation stage. The data from the placebo patients will not be analyzed to inform dose escalation but included in the final analysis upon study completion. Upon the completion of the dose escalation stage, the MTD will be selected using isotonic regression. MTD will be selected as the dosage for which the isotonic estimate of the toxicity rate is closest to the target dosage-limiting toxicity rate (30%). If there is a tie, we will select the higher dosage level when the isotonic estimate is lower than the target toxicity rate, and we will select the lower dosage level when the isotonic estimate is greater than or equal to the target toxicity rate.

During the cohort expansion stage, patients will be randomized to tirofiban at MTD and placebo at the corresponding dosage level to achieve balanced sample sizes (30 tirofiban at MTD and 30 placebo for any infusion duration, combined from both phases) across the two groups. The analysis of the exploratory endpoints will be performed on the tirofiban patients at MTD and placebo patients with any infusion duration.

An interim pharmacokinetic (PK) analysis will be performed after 10 evaluable patients are treated with tirofiban to determine possible dose modification. At the completion of the study, PK and pharmacodynamic (PD) analysis will be conducted using all evaluable patients treated with tirofiban to determine whether augmented renal clearance in aSAH interacts with the pharmacokinetics and pharmacodynamics of tirofiban.

研究の種類

介入

入学 (推定)

82

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • North Carolina
      • Durham、North Carolina、アメリカ、27710
        • Duke University Health System
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Emad Hasan, MD
        • 主任研究者:
          • Brian Mac Grory, MD
    • Texas
      • Houston、Texas、アメリカ、77030
        • University of Texas Health Sciences Center
        • コンタクト:
        • 主任研究者:
          • Spiros Blackburn, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~85年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion:

  • Age 18-85
  • Baseline Modified Rankin Scale (mRS) 0-3 (pre-SAH)
  • SAH attributed to ruptured cerebral aneurysm
  • Admission Computed Tomography (CT) scan shows Modified Fisher grade 1-4 due to aSAH primarily in the supratentorial space
  • World Federation of Neurosurgical Societies (WFNS) scale grade ≤4 at randomization
  • Onset of symptoms of aSAH (ictus) occurred <72 hours prior to presentation
  • If External Ventricular Drain (EVD) placed, placement is ≥12 hours prior to enrollment
  • All aneurysm(s) suspected to be responsible for the hemorrhage must be secured via Endovascular Coil Embolization with a post-embolization Raymond-Roy Score of 1 (Complete) or 2 (Residual Neck) prior to enrollment
  • Participant can be randomized within 48 hours of aneurysm treatment
  • Participant or participant's legally-authorized representative (LAR) has provided documented informed consent

Exclusion:

  • Angio-negative SAH, defined as a SAH with a digital subtraction angiogram that does not show an intracranial aneurysm

  • Surgical clipping prior of the ruptured aneurysm or any non-ruptured aneurysm on the same admission to enrollment

  • Remaining untreated aneurysm(s) that could reasonably be considered a possible alternate cause of the aSAH based on the observed bleeding pattern

  • Uncontrollable hypertension (>180 systolic and/or >110 diastolic) that is not correctable prior to enrollment

  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure, or severe physical trauma within the previous month (30 days)

  • A medical diagnosis that requires continuous use of aspirin, clopidogrel, ticagrelor, or tirofiban during the study drug infusion

  • New parenchymal hemorrhage or new infarction larger than 15 cubic centimeters (cc) in volume by CT

  • Thrombolytic therapy within 24 hours prior to enrollment (alteplase, tenecteplase, or urokinase)

  • Previous intracranial hemorrhage, intracranial neoplasm, subarachnoid hemorrhage, or arterial-venous malformation

  • Thrombocytopenia (platelet count <100,000/microliter (µL) assuming clumping is ruled out

  • Allergy or intolerance to tirofiban

  • Pregnant or lactating

  • Chronic kidney disease with creatinine clearance (CrCl ≤ 30 milliliters per minute [ml/min]) or acute kidney injury (AKI) at study screening. AKI is defined as:

    i) Increase in serum creatinine by 0.3 milligrams per deciliter (mg/dL) or more (26.5 micromoles per liter [μmol/L] or more) within 48 hour period; OR ii) Increase in serum creatinine to 1.5 times or more than the baseline of the prior 7 day period; OR iii) Urine volume less than 0.5 ml/kg/hour for at least 6 hours

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Tirofiban

Continuous IV infusion of tirofiban for 1, 3, 5, or 7 days post-endovascular coiling.

IV infusion at 0.10 microgram/kilogram/minute (mcg/kg/min) for 1 day, 3 days, 5 days, or 7 days according to the dose escalation procedure.

他の名前:
  • アグラスタット ®
プラセボコンパレーター:Placebo

Continuous IV infusion of saline placebo for 1, 3, 5, or 7 days post-endovascular coiling.

IV infusion at the same infusion duration as the study drug; same adjustments

他の名前:
  • 生理食塩水

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Tirofiban dosage-limiting toxicity (DLT)
時間枠:Within 14 days post-randomization

Presence of any of the following: any intracranial hemorrhage, major extracranial hemorrhage (defined as clinically overt bleeding leading to death; OR clinically overt bleeding causing a reduction in hemoglobin of ≥2g/dl; OR clinically overt bleeding necessitating transfusion of ≥2 units of packed red cells or whole blood; OR clinically overt bleeding in a critical area or organ other than the intracranial compartment (including intraspinal, intraocular, pericardial, intra-articular, retroperitoneal, intramuscular [with compartment syndrome])), thrombocytopenia, or serious adverse event (SAE) due to tirofiban.

Within 14 days post-randomization

二次結果の測定

結果測定
メジャーの説明
時間枠
薬物動態パラメータ - 全クリアランス (Cltot)
時間枠:薬剤中止後最大7時間
薬剤中止後最大7時間
薬物動態パラメータ - 分布容積 (Vd)
時間枠:薬物中止後最大7時間
薬物中止後最大7時間
Pharmacokinetic parameters - Maximum (peak) plasma concentration (Cmax)
時間枠:Up to 7 hours after drug discontinuation

Highest concentration of tirofiban in the blood after a dose is administered

Up to 7 hours after drug discontinuation
Pharmacokinetic parameters - Minimum (trough) plasma concentration (Cmin)
時間枠:Up to 7 hours after drug discontinuation

Lowest observed concentration of tirofiban in the blood after a dose is administered

Up to 7 hours after drug discontinuation
Pharmacokinetic parameters - Average Plasma Concentration (Cavg)
時間枠:Up to 7 hours after drug discontinuation

Average tirofiban concentration in the blood at steady state

Up to 7 hours after drug discontinuation
Pharmacokinetic parameters - Area Under the Concentration (AUC)Time Curve
時間枠:Up to 7 hours after drug discontinuation

Area under the curve from time 0 extrapolated to infinite time

Up to 7 hours after drug discontinuation
Pharmacodynamic parameters - adenosine diphosphate (ADP)
時間枠:Baseline, 2, 6, and every 24 hours and at drug cessation

The percent inhibition of ADP-induced platelet aggregation

Baseline, 2, 6, and every 24 hours and at drug cessation

その他の成果指標

結果測定
メジャーの説明
時間枠
Delayed cerebral ischemia (DCI) or death without DCI
時間枠:Within 14 days post-randomization

This is the primary exploratory efficacy outcome, which is a composite binary outcome. DCI is defined as any of the following: a. Focal neurological impairment, b. decrease of at least 2 points on the Glasgow coma scale and/or c. cerebral infarction present on final CT or MRI, which was not present on a CT or MRI between 24-48 hours post-endovascular therapy and not attributable to other causes.

Within 14 days post-randomization
Cerebral vasospasm
時間枠:Within 14 days post-randomization or until discharge from the index admission, which occurred later

Cerebral vasospasm requires confirmation of vasospasm on either CTA or DSA confirming mild vasospasm (decrease in vessel diameter by ≤25% of normal artery diameter), moderate vasospasm (decrease in vessel diameter by >25 to ≤50% of normal diameter but cerebral vasospasm), or severe vasospasm (decrease in vessel diameter by >50% of normal vessel diameter)

Within 14 days post-randomization or until discharge from the index admission, which occurred later
Mortality
時間枠:3 and 6 months post-randomization

Death of any cause

3 and 6 months post-randomization
Total number of days in the ICU for the index admission
時間枠:Up to 6 months post-randomization

Total number of days from ICU admission to ICU discharge during the index hospitalization

Up to 6 months post-randomization
Total hospital stay length for the index admission
時間枠:Up to 6 months post-randomization

Total number of days from admission to discharge during the index admission

Up to 6 months post-randomization
Modified Rankin Scale (mRS)
時間枠:3 and 6 months post-randomization

It is a clinician-reported measure of global disability, widely applied for evaluating stroke patient outcomes and as an endpoint in randomized clinical trials. It is a single-item 7-point scale with a range of 0 (no symptoms at all) to 6 (death), with higher scores indicating greater disability.

The elements of the mRS are as follows: (1) no symptoms at all; (2) no significant disability, but there may be slight symptoms such as weakness or numbness; (3) slight disability, but able to carry out daily activities independently; (4) moderate disability, requiring some help with daily activities; (5) moderately severe disability, requiring assistance with most daily activities; (6) severe disability, bedridden and requiring constant nursing care; and (7) death.

3 and 6 months post-randomization
Return to work
時間枠:3 and 6 months post-randomization

Returned to prior level of responsibilities at work

3 and 6 months post-randomization
Lawton Instrumental Activities of Daily Living (Lawton IADL)
時間枠:3 and 6 months post-randomization

It is an instrument to assess independent living skills among older adults, and can be used in community or hospital settings. There are 8 domains of function measured with the scale: (1) using the telephone; (2) shopping; (3) preparing food; (4) housekeeping; (5) doing laundry; (6) using transportation; (7) handling medications; (8) handling finances.

Women are scored on all 8 areas of function; historically, for men, the areas of food preparation, housekeeping, and laundering are excluded. Individuals are scored according to their highest level of functioning in that category. A summary score ranges from 0 (low function, dependent) to 8 (high function, independent) for women, and 0 through 5 for men.

3 and 6 months post-randomization
Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS)
時間枠:3 and 6 months post-randomization

It is a 6-item scale to evaluate the overall satisfaction with facets of life relevant to people with traumatic brain injury. The area covered by the questionnaire includes physical condition, cognition, emotions, function in daily life, personal and social life, and current situation and future prospects.

Responses to each item were scored 1 ('Not at all') to 5 ('Very'), and the sum of all items was converted arithmetically to a percentage scale, with 0 representing the lowest possible (health-related quality of life (HRQoL) on the questionnaire and 100 the best possible HRQoL.

3 and 6 months post-randomization
Glasgow Outcome Scale-Extended (GOS-E)
時間枠:3 and 6 months post-randomization

It is used to assess global outcomes in persons with brain injury, by categorizing global function using an 8-point ordinal scale that focuses on disability and functioning in daily life. The scales are: 1. Dead, 2. Vegetative State, 3. Lower Severe Disability (SD), 4. Upper SD, 5. Lower Moderate Disability (MD), 6. Upper MD, 7. Lower Good Recovery (GR), 8. Upper GR

3 and 6 months post-randomization
PROMIS-29+2
時間枠:3 and 6 months post-randomization

The Patient-Reported Outcomes Measurement Information System® (PROMIS) is a flexible set of tools designed to measure self-reported physical, mental, and social health and wellbeing. PROMIS-29+2 is a collection of 4-item Likert-item short forms assessing the following domains:

  1. Physical function
  2. Anxiety
  3. Depression
  4. Fatigue
  5. Sleep disturbance
  6. Ability to participate in social roles and activities
  7. Pain interference
  8. Cognitive Function - Abilities (2 items)
  9. Pain intensity (single item)

Norm-based scores will be calculated for each domain on the PROMIS measures, so that a score of 50 represents the mean or average of the reference population. A score of 60 means that the person is one standard deviation above the reference population (standard deviation = 10). For PROMIS measures, higher scores equal more of the concept being measured (e.g., more Fatigue, more Physical Function).

3 and 6 months post-randomization
Montreal Cognitive Assessment (MoCA)
時間枠:3 and 6 months post-randomization

It is a 30-point test to assess people for dementia. The MoCA evaluates different types of cognitive abilities, including orientation, short-term memory / delayed recall, executive function / visuospatial ability, language ability, abstraction, animal naming, attention, and clock-drawing. Scores range from 0 to 30, with a score of 26 or higher considered normal.

3 and 6 months post-randomization

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Emad Hasan, MD、Duke University
  • 主任研究者:Brian Mac Grory, MD、Duke University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月5日

一次修了 (推定)

2029年5月5日

研究の完了 (推定)

2032年5月5日

試験登録日

最初に提出

2026年3月10日

QC基準を満たした最初の提出物

2026年3月23日

最初の投稿 (実際)

2026年3月25日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • Pro00119469
  • UG3NS138219 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。